Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3652937 | 0.89 | MLYCD (0.55) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL3050386 | 0.84 | GPBAR1 (0.49) | GPBAR1NOTUMTACR1CES2 | |
| SCHEMBL31048071 | 0.83 | MLYCD (0.50) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL12563345 | 0.83 | MLYCD (0.50) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL1662271 | 0.83 | MLYCD (0.50) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL12187536 | 0.83 | MLYCD (0.50) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL13715456 | 0.83 | MLYCD (0.50) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL4757590 | 0.82 | MLYCD (0.49) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL14355588 | 0.82 | NOTUM (0.63) | MLYCDGPBAR1NOTUMTACR1CES2 | |
| SCHEMBL1189827 | 0.82 | MLYCD (0.49) | MLYCDGPBAR1NOTUMTACR1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED | 2022-10-13 | — | — | US | disclosed |
| WO-2022212531-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | RSU1, SOST, CCNA1 | MLYCD 4685/4885GPBAR1 1810/4885NOTUM 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.